Gain Therapeutics joins H.C. Wainwright Global Investment Conference for investor meetingsPUBT·2 days ago, 06:02 AMGANX+2.21%
Gain Therapeutics Q2 FY26 net loss narrows to $0.11 a share; R&D expenses fall 24.64% to $2.1 millionPUBT·Aug 11 at 06:04 AMGANX+2.21%
The American Economy in 2026 Is Splintering: What Ten Outliers RevealGlobal Report·Aug 5 at 04:13 AMALL-1.60%NYT-0.44%
The Unbundled Tail of the Market: From Volatility ETFs to Binary BiotechGlobal Report·Jul 29 at 04:19 AMULS+0.67%RIG+2.50%
Market Insider: EV Charging Realities, Pharma Breakouts, and Under-the-Radar MoversGlobal Report·Jul 21 at 04:13 AMALAR-1.20%AUMN-2.27%
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational UpdateUnusual Whales·Jul 16 at 06:03 AMGANX+2.21%
Gain Therapeutics names Joanne Taylor chief scientific officer, promotes Terenzio Ignoni to COOPUBT·Jul 16 at 06:03 AMGANX+2.21%
Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target UnchangedTip Ranks·Jul 2 at 01:45 PMGANX+2.21%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·Jun 29 at 04:05 PMNVCT+0.76%ECOR-6.18%
Gain Therapeutics wins FDA IND clearance for Parkinson’s drug GT-02287 phase 2 trialPUBT·Jun 29 at 03:06 PMGANX+2.21%
